<DOC>
	<DOC>NCT01189279</DOC>
	<brief_summary>This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Males with moderate malepattern baldness (androgenic alopecia) Females with moderate female pattern hair loss Nonsmoker or smoker with at least 30 days abstinence from smoking/using nicotinecontaining products Any dermatological condition of the scalp other than androgenic alopecia (males) or female pattern hair loss (females) Use of bimatoprost or other prostaglandin analogs within 3 months Prior use of scalp hair growth treatment (eg, finasteride, minoxidil) within 6 months Any prior hair growth procedures (eg, hair transplant or laser) Blood donation or equivalent blood loss within 90 days History of alcohol or drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>